Corvus Pharmaceuticals, Inc. - 8-K Filing
Corvus Pharmaceuticals reported $236.7 million in cash, cash equivalents, and marketable securities as of March 31, 2026, up from $56.8 million as of December 31, 2025, largely due to $189.4 million in net proceeds from a January 2026 financing. The company incurred a net loss of $13.7 million for the first quarter of 2026, compared to net income of $15.2 million in the same period in 2025. The increase in R&D expenses to $11.2 million was driven by higher clinical trial costs and personnel expenses. The company also provided an update on its clinical trials for soquelitinib, including the ini... (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $CRVS